tbuckley/cabot-search huggingface dataset:
Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.
Authors: John M. Pagel, Ted Gooley, Effie W. Petersdorf, Mari Malkki, Lacey Drouet, Ann Woolfrey, John A. Hansen, Frederick R. Appelbaum
Journal: Blood (2007)
A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp
Authors: J. Weiss, M. Ulrich, M. Bukhalo, M.L. Østerdal, B. Bang, C.W. Hanke
Journal: British Journal of Dermatology (2017)

Actinic keratosis (AK) is a common sun‐related skin condition, which can progress to squamous cell carcinoma and occur in cancerized fields. To investigate in a phase I/II trial the safety and efficacy of ingenol disoxate as topical field therapy for patients with AK on the balding scalp. Part 1 was a phase I, open‐label, dose‐escalation trial investigating up to six doses of ingenol disoxate to determine the maximum tolerated dose (MTD). Part 2 was a phase II, randomized, double‐blind, parallel group, vehicle‐controlled trial. Patients were randomized 2 : 2 : 1 to receive ingenol disoxate 0·037%, 0·05% or vehicle gel once daily for two consecutive days. Percentage reduction in AK count from baseline, complete clearance (AKCLEAR 100) and partial clearance (≥ 75% AK count reduction; AKCLEAR 75) were assessed at week 8. The MTD in part 1 was 0·075% based on a dose‐dependent increase in the number and severity of adverse events. Two lower doses of ingenol disoxate gel (0·037%, 0·05%) were assessed in part 2, which showed a reduction in AK count from baseline to week 8 (0·037%, 72·7%; 0·05%, 78·5% vs. vehicle 12·6; P < 0·001), and rates of AKCLEAR 100 and AKCLEAR 75 were significantly higher in active treatment groups compared with vehicle (P ≤ 0·007). Local skin responses peaked at day 3 and declined rapidly. Adverse events were generally mild to moderate in intensity, and were most commonly application site pain/pruritus. Ingenol disoxate 0·037% and 0·05% gel was effective and superior to vehicle, and well tolerated as field therapy for AK on the balding scalp.
Tet2 Negatively Regulates Homeostasis and Differentiation of Hematopoietic Stem Cells in Mice
Authors: Myunggon Ko, Hozefa S. Bandukwala, Jungeun An, Edward D. Lamperti, Elizabeth C. Thompson, Ryan Hastie, Angeliki Tsangaratou, Klaus Rajewsky, Sergei B. Koralov, Anjana Rao
Journal: Blood (2011)
Association of Body Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations to Cardiometabolic Disease: A Mendelian Randomization Approach
Authors: Michael M. Mendelson, Riccardo E. Marioni, Roby Joehanes, Chunyu Liu, Åsa K. Hedman, Stella Aslibekyan, Ellen W. Demerath, Weihua Guan, Degui Zhi, Chen Yao, Tianxiao Huan, Christine Willinger, Brian Chen, Paul Courchesne, Michael Multhaup, Marguerite R. Irvin, Ariella Cohain, Eric E. Schadt, Megan L. Grove, Jan Bressler, Kari North, Johan Sundström, Stefan Gustafsson, Sonia Shah, Allan F. McRae, Sarah E. Harris, Jude Gibson, Paul Redmond, Janie Corley, Lee Murphy, John M. Starr, Erica Kleinbrink, Leonard Lipovich, Peter M. Visscher, Naomi R. Wray, Ronald M. Krauss, Daniele Fallin, Andrew Feinberg, Devin M. Absher, Myriam Fornage, James S. Pankow, Lars Lind, Caroline Fox, Erik Ingelsson, Donna K. Arnett, Eric Boerwinkle, Liming Liang, Daniel Levy, Ian J. Deary
Journal: PLoS Medicine (2017)

The link between DNA methylation, obesity, and adiposity-related diseases in the general population remains uncertain.We conducted an association study of body mass index (BMI) and differential methylation for over 400,000 CpGs assayed by microarray in whole-blood-derived DNA from 3,743 participants in the Framingham Heart Study and the Lothian Birth Cohorts, with independent replication in three external cohorts of 4,055 participants. We examined variations in whole blood gene expression and conducted Mendelian randomization analyses to investigate the functional and clinical relevance of the findings. We identified novel and previously reported BMI-related differential methylation at 83 CpGs that replicated across cohorts; BMI-related differential methylation was associated with concurrent changes in the expression of genes in lipid metabolism pathways. Genetic instrumental variable analysis of alterations in methylation at one of the 83 replicated CpGs, cg11024682 (intronic to sterol regulatory element binding transcription factor 1 [SREBF1]), demonstrated links to BMI, adiposity-related traits, and coronary artery disease. Independent genetic instruments for expression of SREBF1 supported the findings linking methylation to adiposity and cardiometabolic disease. Methylation at a substantial proportion (16 of 83) of the identified loci was found to be secondary to differences in BMI. However, the cross-sectional nature of the data limits definitive causal determination.We present robust associations of BMI with differential DNA methylation at numerous loci in blood cells. BMI-related DNA methylation and gene expression provide mechanistic insights into the relationship between DNA methylation, obesity, and adiposity-related diseases.
A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia.
Authors: Januario E. Castro, William G. Wierda, Thomas J. Kipps, Michael J. Keating, Jan Bole, Blanche Anderson, Jayne Meyer, Mark Bonyhadi, Ronald J. Berenson, Mark W. Frohlich
Journal: Blood (2004)
Association of Periodic Discharges With Reduced Brain Tissue Oxygenation
Authors: Brian D. Moseley
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.
Authors: Yong-Mi Kim, Eugene Park, Colin Lorentzen, Brian De La Torre, Yao-Te Hsieh, Hannah Whang, Lars Klemm, Cu Nguyen, Michael McMillan, Jia-Ling Teo, Markus Muschen, Michael Kahn
Journal: Blood (2007)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)
Authors: Gustaaf W van Imhoff, Andrew McMillan, Matthew J. Matasar, John Radford, Kirit M Ardeshna, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, Michael Fennessy, Qiming Liao, Bronno van der Holt, Steen Lisby, Thomas S. Lin, Anton Hagenbeek
Journal: Blood (2014)
Technetium99msestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting
Authors: Gregory S. Thomas, Michael I. Miyamoto, A.Peter Morello, Haresh Majmundar, Jennifer J. Thomas, Christine H. Sampson, Rory Hachamovitch, Leslee J. Shaw
Journal: Journal of the American College of Cardiology (2004)
Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group
Authors: Enrique M. Ocio, Cristina Motlló, Paula Rodriguez-Otero, Joaquín Martínez-López, Javier De La Rubia, Mieke Ptaszynski, Brian Tunquist, Ramon Garcia-Sanz, Albert Oriol, Juan José Lahuerta, Jesús San-Miguel, Maria-Victoria Mateos
Journal: Blood (2016)
Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus
Authors: Denis Comte, Maria P. Karampetsou, Nobuya Yoshida, Katalin Kis‐Toth, Vasileios C. Kyttaris, George C. Tsokos
Journal: Arthritis & Rheumatology (2017)

Effector CD8+ T cell function is impaired in systemic lupus erythematosus (SLE) and is associated with a compromised ability to fight infections. Signaling lymphocytic activation molecule family member 7 (SLAMF7) engagement has been shown to enhance natural killer cell degranulation. This study was undertaken to characterize the expression and function of SLAMF7 on CD8+ T cell subsets isolated from the peripheral blood of SLE patients and healthy subjects.CD8+ T cell subset distribution, SLAMF7 expression, and expression of cytolytic enzymes (perforin, granzyme A [GzmA], and GzmB) on cells isolated from SLE patients and healthy controls were analyzed by flow cytometry. CD107a expression and interferon-γ (IFNγ) production in response to viral antigenic stimulation in the presence or absence of an anti-SLAMF7 antibody were assessed by flow cytometry. Antiviral cytotoxic activity in response to SLAMF7 engagement was determined using a flow cytometry-based assay.The distribution of CD8+ T cell subsets was altered in the peripheral blood of SLE patients, with a decreased effector cell subpopulation. Memory CD8+ T cells from SLE patients displayed decreased amounts of SLAMF7, a surface receptor that characterizes effector CD8+ T cells. Ligation of SLAMF7 increased CD8+ T cell degranulation capacity and the percentage of IFNγ-producing cells in response to antigen challenge in SLE patients and healthy controls. Moreover, SLAMF7 engagement promoted cytotoxic lysis of target cells in response to stimulation with viral antigens.CD8+ T cell activation in response to viral antigens is defective in SLE patients. Activation of SLAMF7 through a specific monoclonal antibody restores CD8+ T cell antiviral effector function to normal levels and thus represents a potential therapeutic option in SLE.
Improvement in Hemolytic Parameters and Tricuspid Regurgitant Jet Velocity (TRV) Following Non-Myeloablative Allogeneic Stem Cell Transplantation (allo-SCT) in Adults with Severe Sickle Cell Disease (SCD).
Authors: Matthew M. Hsieh, Beth Link, Roberto Machado, Gregory Kato, Mark Gladwin, John F. Tisdale
Journal: Blood (2007)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Authors: Gurkan Mollaoglu, Matthew R. Guthrie, Stefanie Böhm, Johannes Brägelmann, Ismail Can, Paul M. Ballieu, Annika Marx, Julie George, Christine Heinen, Milind D. Chalishazar, Haixia Cheng, Abbie S. Ireland, Kendall E. Denning, Anandaroop Mukhopadhyay, Jeffery M. Vahrenkamp, Kristofer C. Berrett, Timothy L. Mosbruger, Jun Wang, Jessica L. Kohan, Mohamed E. Salama, Benjamin L. Witt, Martin Peifer, Roman K. Thomas, Jason Gertz, Jane E. Johnson, Adi F. Gazdar, Robert J. Wechsler-Reya, Martin L. Sos, Trudy G. Oliver
Journal: Cancer Cell (2017)
The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome
Authors: Tow Shung Tan, Angela Dispenzieri, Rajiv Pruthi, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Steven R. Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Shaji Kumar
Journal: Blood (2008)
The Role of Labile Plasmatic Iron (LPI) In the Assessment of Iron Overload In β-Thalassemic Patients and Its Correlation with MRI Findings
Authors: Reiĵne Alves de Assis, Breno Pannia Espósito, Fernando Uliana Kay, Ronaldo Hueb Baroni, Laercio Alberto Rosemberg, Cesar Higa Nomura, Andreza Alice Feitosa Ribeiro, Sandra Regina Loggetto, Mônica Pinheiro de Almeida Veríssimo, Antonio Fabron Junior, Aderson S Araujo, Giorgio Roberto Baldanzi, Sandra Saemi Nakashima, Michelli da Silva Diniz, Merula Steagal, Claudia Angela Galenni di Sessa Velloso, Marcelo Buarque de Gusmão Funari, John Wood, Nelson Hamerschlak
Journal: Blood (2010)
Mechanism of Neonicotinoid Toxicity: Impact on Oxidative Stress and Metabolism
Authors: Xu Wang, Arturo Anadón, Qinghua Wu, Fang Qiao, Irma Ares, María-Rosa Martínez-Larrañaga, Zonghui Yuan, María-Aránzazu Martínez
Journal: The Annual Review of Pharmacology and Toxicology (2017)

Thousands of tons of neonicotinoids are widely used around the world as broad-spectrum systemic insecticides and veterinary drugs. Researchers originally thought that neonicotinoids exhibited low mammalian toxicity. However, following their widespread use, it became increasingly evident that neonicotinoids could have various toxic effects on vertebrates and invertebrates. The primary focus of this review is to summarize the research progress associated with oxidative stress as a plausible mechanism for neonicotinoid-induced toxicity as well as neonicotinoid metabolism. This review summarizes the research conducted over the past decade into the production of reactive oxygen species, reactive nitrogen species, and oxidative stress as aresult of neonicotinoid treatments, along with their correlation with the toxicity and metabolism of neonicotinoids. The metabolism of neonicotinoids and protection of various compounds against neonicotinoid-induced toxicity based on their antioxidative effects is also discussed. This review sheds new light on the critical roles of oxidative stress in neonicotinoid-induced toxicity to nontarget species.
Effect of Polymorphisms in p53 Pathway Proteins and B-Chronic Lymphocytic Leukemia Disease Progression,
Authors: Hyunjoo Lee, Anthony Liew, Annette Lee, Shabirul Haque, Jonathan E Kolitz, Steven L. Allen, Kanti R. Rai, Peter Gregersen, Charles C. Chu, Nicholas Chiorazzi, Patricia Mongini
Journal: Blood (2011)
Antitumor activity of nexil in preclinical animal tumor models
Authors: Zhongling Feng, Sanjib Das, Fu Chen, Gang Zhao, Stephen Howell, Lei Yu
Journal: Cancer Research (2008)

2319  Background: Nexil, poly-(γ-L-glutamyl glutamine)-paclitaxel, is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel by enhancing delivery via the enhanced permeability and retention mechanism. It is a water-soluble formulation of paclitaxel (PTX) made by conjugating PTX to poly(L-glutamate glutamate acid) via ester bonds. Nexil spontaneously forms nanoparticles in aqueous environments. In this study, we evaluated the activity of a Nexil by IV injection in mice bearing a human non-small cell lung cancer xenograft. Methods: The maximum tolerated dose (MTD) of Nexil was determined in tumor free and tumor-bearing nude mice. Therapeutic efficacy of Nexil as compared to Abraxane was evaluated in both the NCI-H460 non-small cell lung cancer xenograft and murine B16 melanoma models. Results: Nexil is ready soluble in 0.9% saline at 50 mg/ml. Analysis of particle size by light scattering demonstrated that 90% of the particles had a diameter between 7 and 10 nm. In NCI-H460 non-small cell lung cancer xenograft model, when given on a q7dx2 schedule, the MTD of Abraxane given IV was 200 mg/kg total cumulative dose; the MTD of Nexil given IV on the same schedule was 1100 mg/kg total cumulative dose. When both drugs were given on the q7dx2 schedule Nexil demonstrated antitumor activity that was significantly better than that of Abraxane while producing less weight loss (Nexil 12%, Abraxane 25%). Nexil increased tumor growth delay by 136% relative to that produced by Abraxane. In the B16 murine melanoma model, Nexil also demonstrated superior antitumor activity at 200 mg/kg/d on a qdx2 schedule given IV; Nexil produced a tumor growth delay 50% greater than that produced by Abraxane. Nexil has also shown activity HT-29 human colon carcinoma model. Conclusions: Covalent linkage of paclitaxel to the poly-(γ-L-glutamyl glutamine) backbone resulted in a formulation that retains high solubility and spontaneously forms nanoparticles in a range known to accumulate in tumors with hyperpermeable capillaries. The toxicity of Nexil was substantially lower than that of Abraxane as estimated from MTD. Nexil has activity in a murine and several human tumor models, and is superior to Abraxane in the NCI-H460 non-small cell lung cancer model. These results encourage the development of Nexil as a Cremophor-free polymer based formulation of paclitaxel for the treatment of malignant diseases.
Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms
Authors: Meng Ling Choong, Christian Pecquet, Shi Jing Tai, Jacklyn WY Yong, Vishal Pendharkar, SiFang Wang, Jean-Philippe Defour, Carmen C. Diaconu, Kanda Sangthongpitag, Jean-Luc Villeval, William Vainchenker, Stefan N. Constantinescu, May Ann Lee
Journal: Blood (2012)
Smoking cessation for people with severe mental ill health (SCIMITAR): results from a pilot randomised controlled trial
Authors: S Gilbody, Emily Peckham, Mei-See Man, Natasha Mitchell, Jinshuo Li, Taeko Becque, Catherine Hewitt, Sarah Knowles, Timothy Bradshaw, Claire Planner, Steve Parrott, Susan Michie, Charles Shepherd
Journal: The Lancet Psychiatry (2015)
Can preoperative assessment of cancer in the elderly (PACE) predict 30-days postoperative outcomes?
Authors: R. A. Audisio, H. S. Ramesh, R. Gennari, G. Corsini, M. Maffezzini, H. J. Hoekstra, D. Mobarak, F. Bozzetti, M. Colledan, H. Wildiers, D. P. Pope
Journal: Journal of Clinical Oncology (2006)

8537 Background: Surgery is the treatment of choice for solid cancers. Frequent functional impairment/comorbidities in the elderly enhances the risk of treatment related complications. Inability to forecast short term outcomes after cancer surgery in elderly affects clinical practice, denying optimal treatment. No validated instrument is available to help make informed decision; a compilation of validated questionnaires (PACE) is established to preoperatively inform on the health condition of elderly cancer pts. This international multicentre study investigates how components of PACE preoperatively assessed are associated with postoperative outcomes. Methods: A prospective series of consenting elderly cancer pts (≥70 yrs) receiving elective surgery (moderate-major+) were recruited from 8 hospitals (UK, Netherlands, Italy, Japan, Belgium) (07/2003–12/2005) and assessed using PACE (Comorbidities, IADL, ADL, GDS, BFI, PS, MMS, ASA). 30day morbidity, hospital stay and mortality were recorded. Results: 448 pts [breast (48%), GI (30%), GU (16%), miscellaneous (6%)] were recruited and followed postoperatively. Observed morbidity was 36% (161 pts), mortality 4% (16 pts) and median hospital stay was 5 days (range 2 -10). All components of PACE but ASA were associated with morbidity (p&lt;0.05) and hospital stay (p&lt;0.05) on univariate analysis. Operative deaths were too few to look for associations. Forward stepwise logistic regression models (multivariate analysis) identified 3 components of PACE as best describing the occurrence of post-surgical morbidity: BFI (OR (upper quartile)= 2.4; 95% CI=1.2–4.9); PS (OR=1.9; 95% CI=1.1–3.4); IADL (OR=1.7; 95% CI=1.0–3.0). The same components were also selected into the model as best describing hospital stay beyond average: BFI (OR (upper quartile)=18.1; 95% CI=7.2–45.3), PS (OR=2.2; 95%=1.2–4.4) and IADL (OR=2.7; 95% CI=1.4–5.1). Of those pts exposed to all 3 factors entered into the regression models 61% experienced complications and &gt;80% had a longer hospital stay. Conclusions: BFI, PS and IADL appear to be the most relevant prognosticators of short term surgical outcomes. A holistic appraisal of elderly pts undergoing surgery is warmly recommended when consenting the patient and during the decision making process. No significant financial relationships to disclose.
Decline in Cardiovascular Mortality
Authors: George A. Mensah, Gina S. Wei, Paul D. Sorlie, Lawrence J. Fine, Yves Rosenberg, Peter G. Kaufmann, Michael E. Mussolino, Lucy L. Hsu, Ebyan Addou, Michael M. Engelgau, David Gordon
Journal: Circulation Research (2017)

If the control of infectious diseases was the public health success story of the first half of the 20th century, then the decline in mortality from coronary heart disease and stroke has been the success story of the century's past 4 decades. The early phase of this decline in coronary heart disease and stroke was unexpected and controversial when first reported in the mid-1970s, having followed 60 years of gradual increase as the US population aged. However, in 1978, the participants in a conference convened by the National Heart, Lung, and Blood Institute concluded that a significant recent downtick in coronary heart disease and stroke mortality rates had definitely occurred, at least in the US Since 1978, a sharp decline in mortality rates from coronary heart disease and stroke has become unmistakable throughout the industrialized world, with age-adjusted mortality rates having declined to about one third of their 1960s baseline by 2000. Models have shown that this remarkable decline has been fueled by rapid progress in both prevention and treatment, including precipitous declines in cigarette smoking, improvements in hypertension treatment and control, widespread use of statins to lower circulating cholesterol levels, and the development and timely use of thrombolysis and stents in acute coronary syndrome to limit or prevent infarction. However, despite the huge growth in knowledge and advances in prevention and treatment, there remain many questions about this decline. In fact, there is evidence that the rate of decline may have abated and may even be showing early signs of reversal in some population groups. The National Heart, Lung, and Blood Institute, through a request for information, is soliciting input that could inform a follow-up conference on or near the 40th anniversary of the original landmark conference to further explore these trends in cardiovascular mortality in the context of what has come before and what may lie ahead.
Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≤ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial.
Authors: Boris Labar, Stefan Suciu, Petra Muus, Roelof Willemze, Jean-Pierre Marie, Georges Fillet, Zwi Berneman, Branimir Jaksic, Walter Feremans, Dominique Bron, Henry Sinnige, Martin Mistrik, G. Vreugdenhil, Robrecht De Bock, Damir Nemet, Caroline Gilotay, Theo de Witte, Sergio Amadori
Journal: Blood (2005)
Multislice computed tomography versus intracardiac echocardiography to evaluate the pulmonary veins before radiofrequency catheter ablation of atrial fibrillation
Authors: Monique R.M. Jongbloed, Jeroen J. Bax, Hildo J. Lamb, Martijn S. Dirksen, K. Zeppenfeld, Ernst E. van der Wall, Albert de Roos, Martin J. Schalij
Journal: Journal of the American College of Cardiology (2005)
Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
Authors: Andre Baruchel, Yves Bertrand, Xavier Thomas, Nicolas Blin, Emmanuelle Tavernier, Stephane Ducassou, Norbert Vey, Virginie Gandemer, Victoria Cacheux, Francoise Mazingue, Emmanuel Raffoux, Genevieve PLAT, Jose Fernandes, Poiree Maryline, Luc Fornecker, Jean-Louis Stephan, Mathilde Hunault, Anne Auvrignon, Thibault Leguay, Dominique Plantaz, Stephane Lepretre, Alina Ferster, Isabelle Pellier, Emmanuel Plouvier, Claudine Schmitt, Cecile Bonin, Iman El Hariry
Journal: Blood (2015)
Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies
Authors: Piotr Smolewski, Robak Pawel, Barbara Cebula-Obrzut, Malgorzata Misiewicz, Aleksandra Jeske, Agata Majchrzak, Scott Stromatt, Tadeusz Robak
Journal: Blood (2011)